361 related articles for article (PubMed ID: 11758573)
1. FDA's role in making exclusivity determinations.
Dickinson EH
Food Drug Law J; 1999; 54(2):195-203. PubMed ID: 11758573
[No Abstract] [Full Text] [Related]
2. FDA's role in administering the Hatch-Waxman Act.
Malkin BJ
Food Drug Law J; 1999; 54(2):211-4. PubMed ID: 11758575
[No Abstract] [Full Text] [Related]
3. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry.
Srivastava D
Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015
[No Abstract] [Full Text] [Related]
4. A new history and discussion of 180-day exclusivity.
Korn DE; Lietzan E; Scott SW
Food Drug Law J; 2009; 64(2):335-90. PubMed ID: 19999288
[TBL] [Abstract][Full Text] [Related]
5. Drug marketing exclusivity under United States and European Union law.
Junod V
Food Drug Law J; 2004; 59(4):479-518. PubMed ID: 15875347
[No Abstract] [Full Text] [Related]
6. GATT implementation and generic drug approval.
Safir PO; Lassman SM
Food Drug Law J; 1996; 51(2):295-302. PubMed ID: 11820203
[No Abstract] [Full Text] [Related]
7. Issues in the interpretation of 180-day exclusivity.
Lietzan E; Korn DE
Food Drug Law J; 2007; 62(1):49-75. PubMed ID: 17444026
[No Abstract] [Full Text] [Related]
8. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
9. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
10. Investigational new drugs: export requirements for unapproved new drug products. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2005 Nov; 70(225):70720-30. PubMed ID: 16304736
[TBL] [Abstract][Full Text] [Related]
11. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
12. Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity.
Morag-Sela T; Cohn I; Kowalski TJ; Jarecki-Black J; Clyde-Watson Z
Nat Biotechnol; 2004 Dec; 22(12):1591-2. PubMed ID: 15583670
[No Abstract] [Full Text] [Related]
13. Old drugs, new uses: solving a Hatch-Waxman patent predicament.
McPhie DC
Food Drug Law J; 2004; 59(1):155-68. PubMed ID: 15190929
[No Abstract] [Full Text] [Related]
14. 2004 update--180-day exclusivity under the Hatch-Waxman amendments to the federal Food, Drug, and Cosmetic Act.
Lietzan EK
Food Drug Law J; 2004; 59(4):459-63. PubMed ID: 15875350
[TBL] [Abstract][Full Text] [Related]
15. Staving off death: a case study of the pharmaceutical industry's strategies to protect blockbuster franchises.
Gorlin DI
Food Drug Law J; 2008; 63(4):823-64. PubMed ID: 19601385
[No Abstract] [Full Text] [Related]
16. The Drug Price Competition and Patent Term Restoration Act of 1984: fine-tuning the balance between the interests of pioneer and generic drug manufacturers.
Soehnge H
Food Drug Law J; 2003; 58(1):51-80. PubMed ID: 12739584
[No Abstract] [Full Text] [Related]
17. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
18. The History and Political Economy of the Hatch-Waxman Amendments.
Lietzan E
Seton Hall Law Rev; 2019; 49(1):53-127. PubMed ID: 30557922
[No Abstract] [Full Text] [Related]
19. Applications for FDA approval to market a dew drug: patent submission and listing requirements and application of 30-month stays on approval of abbreviated new drug applications certifying that a patent claiming a drug is invalid or will not be infringed. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Jun; 68(117):36675-712. PubMed ID: 12814136
[TBL] [Abstract][Full Text] [Related]
20. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
[Next] [New Search]